Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study

@article{Shinsako2010TolerableST,
  title={Tolerable sorafenib therapy for a renal cell carcinoma patient with hemodialysis: a case study},
  author={Keiko Shinsako and Tomoyuki Mizuno and Tomohiro Terada and Jun Watanabe and Tomonari Kamba and Eijiro Nakamura and Osamu Ogawa and Ken-ichi Inui},
  journal={International Journal of Clinical Oncology},
  year={2010},
  volume={15},
  pages={512-514}
}
Sorafenib (Nexavar®) has been approved for the treatment of advanced renal cell carcinoma (RCC) and hepatocellular carcinoma. There is little information on the dosage adjustment of sorafenib for patients with end-stage renal failure. Herein, we have examined the effect of hemodialysis on the pharmacokinetics of sorafenib and its major active metabolite, M-2, and assessed sorafenib-related toxicity throughout the therapy. The patient was a 54-year-old man who was diagnosed with advanced RCC… CONTINUE READING

Similar Papers

Loading similar papers…